Arvinas’ vepdegestrant (VEPPANU) demonstrated a 43% reduction in risk of disease progression versus fulvestrant in the pivotal VERITAC-2 …
Arvinas’ vepdegestrant (VEPPANU) demonstrated a 43% reduction in risk of disease progression versus fulvestrant in the pivotal VERITAC-2 …
Shionogi’s ensitrelvir becomes the only approved oral option for preventing COVID-19 following known exposure, filling a gap left …
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery …
Four-year open-label extension data for zorevunersen reinforce the antisense oligonucleotide’s disease-modifying potential in SCN1A-linked epilepsy, as the pivotal …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to …
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal lobe …
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a …
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
Arvinas’s vepdegestrant (VEPPANU) marks a regulatory milestone as the first proteolysis-targeting chimera to win FDA approval, offering a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
